Neuroblastoma is a pediatric solid tumor that arises from precursor cells of the sympathetic nervous system. 1 Narita et al. 2 published an interesting report that the promoter region of the TLX2 (NCX, Hox11L1, ENX) gene, a member of the HOX11 homeobox gene family, might be used to selectively express potential therapeutic gene sequences in neuroblastoma cells, allowing targeted expression of a suicide gene in cancer cells. The approach of conditional expression of a gene therapy has been successfully developed and tested using a variety of disease-or cell-specific promoters. 3, 4 The rationale for using the TLX2 gene promoter to achieve neuroblastomaspecific expression was that expression of the endogenous TLX2 gene is primarily confined to neural crest-derived tissues. 2, [5] [6] [7] The NCX1.7-luc vector is a modified pGL2-basic vector containing a 1.7-kb region of the NCX promoter upstream of the ATG start codon, which was generated through sequential deletions of genomic DNA of the NCX gene. 2 This promoter region was activated in neuroblastoma cells and expression was measured as a function of luciferase expression. Notably, Narita et al. demonstrated that transfection of this construct into six neuroblastoma cell lines (SH-SY5Y, NGP, NMB, NBL-S, NLF and SMS-SAN) resulted in luciferase expression, but not in negative controls, which included fibroblasts (HFF, MRC-5 and CDC18Co), melanoma (A875), pancreatic cancer (AsPC-1) and lung carcinoma (QG56) cell lines. Our group has identified miRNAs that have anti-proliferative effects when ectopically up-regulated in neuroblastoma cell lines. 8, 9 Therefore, we were interested in validating the cell specificity of NCX1.7-luc expression for use in microRNA-mediated therapeutics. The NCX1.7-luc vector was transfected into nine neuroblastoma cell lines (Kelly, SKNDZ, NGP, IMR-32, SKNBE, SKNAS, LAN-6, SH-SY5Y and SHEP T21N (a non-MYCN amplified cell line containing a tetracycline repressible MYCN expression construct)), and in several putative negative controls, including human embryonic kidney (HEK293) cells, cervical cancer (HeLa) cells, breast cancer (MDA-MB-231 and Hs578T) cells and human astrocytoma glioblastoma (U373MG) cells.
As expected, we confirmed that the NCX1.7-luc vector was expressed in all neuroblastoma cell lines, although expression in one cell line, SK-N-AS, was low ( Figure 1) . Surprisingly, however, NCX1.7-luc expression was also noted in breast cancer (MDA-MB-231 and Hs578T), HeLa and U373MG cell lines to a greater degree than several of the NBL cell lines when compared with luciferase expression in HEK293-transfected cells (Figure 1) . Consistent with our experimental observations is the fact that endogenous TLX2 gene expression occurs in a number of non-neuroblastoma tissues, as indicated by the Oncogenomics Normal Tissue Database. 10 These include the heart, bladder, cerebrum, adrenal glands and intestines, a fact that was also reiterated by Borghini et al.
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In summary, our results indicate that ectopic expression of NCX1.7-luc is not as specific to neuroblastoma cells as previously thought, leading us to conclude that the TLX2 promoter cannot be considered to be cell or tissue-specific with regard to generating conditional gene therapies for neuroblastoma. 
